Adamu Onu

Dr. Adamu Onu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2025 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
MEMichael Enwere
Michael Enwere
EIEdward Irobi
Edward Irobi
AOAdamu Onu
Adamu Onu
EDEmmanuel Davies
Emmanuel Davies
GOGbadebo Ogungbade
Gbadebo Ogungbade
LJLaurens Holmes, Jr
Laurens Holmes, Jr
Background: The human gut microbiome—a diverse ecosystem of trillions of microorganisms—plays an essential role in metabolic, immune, and neurological regulation. However, modern lifestyle factors such as antibiotic overuse, cesarean delivery, reduced breastfeeding, processed and high-sodium diets, alcohol intake, smoking, and exposure to environmental toxins (e.g., glyphosate) significantly reduce microbial diversity. Loss of keystone species like Bifidobacterium infantis (B. infantis) and Lactobacillus reuteri (L. reuteri) contributes to gut dysbiosis, which has been implicated in chronic metabolic, autoimmune, cardiovascular, and neurodegenerative conditions. Materials and Methods: This Qualitative Systematic Review (QualSR) synthesized data from over 547 studies involving human participants and standardized microbiome analysis techniques, including 16S rRNA sequencing and metagenomics. Studies were reviewed for microbial composition, immune and metabolic biomarkers, and clinical outcomes related to microbiome restoration strategies. Results: Multiple cohort studies have consistently reported a 40–60% reduction in microbial diversity among Western populations compared to traditional societies, particularly affecting short-chain fatty acid (SCFA)-producing bacteria. Supplementation with B. infantis is associated with a significant reduction in systemic inflammation—including a 50% decrease in C-reactive protein (CRP) and reduced tumor necrosis factor-alpha (TNF-α) levels—alongside increases in regulatory T cells and anti-inflammatory cytokines interleukin-10 (IL-10) and transforming growth factor-beta 1 (TGF-β1). L. reuteri demonstrates immunomodulatory and neurobehavioral benefits in preclinical models, while both probiotics enhance epithelial barrier integrity in a strain- and context-specific manner. In murine colitis, B. infantis increases ZO-1 expression by ~35%, and L. reuteri improves occludin and claudin-1 localization, suggesting that keystone restoration strengthens barrier function through tight-junction modulation. Conclusions: Together, these findings support keystone species restoration with B. infantis and L. reuteri as a promising adjunctive strategy to reduce systemic inflammation, reinforce gut barrier integrity, and modulate gut–brain axis (GBA) signaling, indicating translational potential in metabolic and neuroimmune disorders. Future research should emphasize personalized microbiome profiling, long-term outcomes, and transgenerational effects of early-life microbial disruption.

22 September 2025 in Onco
Verified
Journal Article
Open access
PDF file
MEMichael Enwere
Michael Enwere
EIEdward Irobi
Edward Irobi
VCVictoria Chime
Victoria Chime
AEAda Ezeogu
Ada Ezeogu
AOAdamu Onu
Adamu Onu
LJLaurens Holmes, Jr
Laurens Holmes, Jr
Background: Despite advances in gene-targeted and immunotherapies, many aggressive cancers—including glioblastoma and triple-negative breast cancer—remain refractory to treatment. Mounting evidence implicates metabolic reprogramming, especially dysregulation of glucose and glutamine metabolism, as a core hallmark of tumor progression. Natural compounds with metabolic-modulatory effects have emerged as promising adjuncts in oncology. Research Question and Objectives: This review investigates the following question: How can metabolic-targeted therapies—particularly those modulating the Warburg effect and glutamine metabolism—improve cancer treatment outcomes, and what role do natural compounds play in this strategy? The objectives were to (1) evaluate the therapeutic potential of metabolic interventions targeting glucose and glutamine metabolism, (2) assess natural compounds with metabolic regulatory activity, (3) examine integration of metabolic-targeted therapies with conventional treatments, and (4) identify metabolic vulnerabilities in resistant malignancies. Methods: A qualitative systematic review (QualSR) was conducted following PRISMA guidelines. A total of 87 peer-reviewed studies published between 2000 and 2024 were included. Inclusion criteria required clearly defined mechanistic or clinical endpoints and, for clinical trials, sample sizes ≥ 30. Data extraction focused on tumor response, survival, metabolic modulation, and safety profiles. Results: Curcumin significantly reduced serum TNF-α and IL-6 (both p = 0.001) and improved antioxidant capacity (p = 0.001). EGCG downregulated ERα (p = 0.002) and upregulated tumor suppressors p53 and p21 (p = 0.001, p = 0.02). High-dose intravenous vitamin C combined with chemoradiotherapy yielded a 44.4% pathologic complete response rate in rectal cancer. Berberine suppressed Akt/mTOR signaling and glutamine transporter SLC1A5 across tumor types (q < 10−10). However, poor bioavailability (e.g., EGCG t½ = 3.4 ± 0.3 h) and systemic toxicity limit their standalone clinical application. Conclusions: Metabolic-targeted therapies—particularly natural compounds acting on glucose and glutamine pathways—offer a viable adjunct to standard cancer therapies. Clinical translation will require biomarker-driven patient stratification, improved delivery systems, and combination trials to optimize the therapeutic impact in treatment-resistant cancers.

13 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MEMichael Enwere
Michael Enwere
EIEdward Irobi
Edward Irobi
AOAdamu Onu
Adamu Onu
EDEmmanuel Davies
Emmanuel Davies
GOGbadebo Ogungbade
Gbadebo Ogungbade
LJLaurens Holmes, Jr
Laurens Holmes, Jr
Background: The human gut microbiome—a diverse ecosystem of trillions of microorganisms—plays a critical role in metabolic, immune, and neurological regulation. However, modern lifestyle factors such as antibiotic overuse, cesarean delivery, reduced breastfeeding, processed and high-sodium diets, alcohol intake, smoking, and exposure to environmental toxins (e.g., glyphosate) have significantly reduced microbial diversity. Loss of keystone species like Bifidobacterium infantis and Lactobacillus reuteri contributes to gut dysbiosis, which has been implicated in chronic metabolic, autoimmune, cardiovascular, and neurodegenerative conditions. Materials & Methods: This Qualitative Systematic Review (QualSR) synthesized data from over 547 studies involving human participants and standardized microbiome analysis techniques, including 16S rRNA sequencing and metagenomics. Studies were reviewed for microbial composition, immune and metabolic biomarkers, and clinical outcomes related to microbiome restoration strategies. Results: Findings reveal a 40–60% reduction in microbial diversity among Western populations compared to traditional societies, particularly affecting SCFA-producing bacteria. Supplementation with B. infantis was associated with a significant reduction in systemic inflammation—including a 50% decrease in C-reactive protein (CRP) and reduced TNF-α levels—alongside increases in regulatory T cells and anti-inflammatory cytokines (IL-10, TGF-β1). L. reuteri demonstrated additional immunomodulatory effects and neurobehavioral benefits in preclinical models. Restoration interventions led to a 30–45% increase in tight junction protein expression and a 25–50% reduction in overall inflammation, suggesting improved gut barrier function and systemic immune balance. Conclusion: Restoring gut microbiota diversity through keystone species like B. infantis and L. reuteri holds therapeutic potential for a wide range of chronic inflammatory, metabolic, and neuroimmune disorders. Strengthening gut barrier integrity and reducing systemic inflammation by up to 50% underscores the microbiome’s relevance in immunometabolic health. Future research should emphasize personalized microbiome profiling, long-term outcomes, and transgenerational effects of early-life microbial disruption.